In this file photo taken on September 10, 2020 a nurse prepares to inoculate volunteer Ilya Dubrovin, 36, with Russia’s new coronavirus vaccine in a post-registration trials at a clinic in Moscow. Russia’s Sputnik V coronavirus vaccine is 95 percent effective according to a second interim analysis of clinical trial data, its developers said on November 24, 2020. The vaccine was developed by the Gamaleya research institute in Moscow in coordination with the Russian defence ministry.
Natalia KOLESNIKOVA / AFP

FILES) In this file photo taken on September 10, 2020 a nurse prepares to inoculate volunteer Ilya Dubrovin, 36, with Russia’s new coronavirus vaccine in a post-registration trials at a clinic in Moscow. Russia’s Sputnik V coronavirus vaccine is 95 percent effective according to a second interim analysis of clinical trial data, its developers said on November 24, 2020. The vaccine was developed by the Gamaleya research institute in Moscow in coordination with the Russian defence ministry.
Natalia KOLESNIKOVA / AFP